year 9, Issue 3 (Autumn 2021)                   Ann Appl Sport Sci 2021, 9(3): 0-0 | Back to browse issues page


XML Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Dergaa I, Abdelrahman H, Varma A, Yousfi N, Souissi A, Ghram A, et al . COVID-19 Vaccination, Herd Immunity and The Transition Toward Normalcy: Challenges with The Upcoming Sports Events. Ann Appl Sport Sci. 2021; 9 (3)
URL: http://aassjournal.com/article-1-1032-en.html
1- PHCC, Primary Health Care Corporation, Doha, Qatar , idergaa@phcc.gov.qa
2- PHCC, Primary Health Care Corporation, Doha, Qatar
3- Research Laboratory “Sport Performance Optimization”, National Centre of Medicine and Science in Sport (CNMSS), Tunis, Tunisia
4- Hamad Bin Khalifa University, College of Health and Life Science
5- HMC, Hamad Medical Corporation, PO Box 3050, Doha, Qatar
6- Department of Sport Sciences, Imam Khomeini International University, Qazvin, Iran
7- Institut Supérieur du Sport et de l’éducation physique de Sfax, Université de Sfax, Sfax, Tunisia. Activité Physique, Sport et Santé, UR18JS01, Observatoire National du Sport, Tunis, Tunisia
8- Depratment of exercise physiology, Faculty of Physical Education & Sport Sciences, University of Tehran, kish International Campus
9- Department of Physical Education and Sport Sciences, Islamic Azad University, Qazvin Branch, Qazvin, Iran
Abstract:   (967 Views)
Background. The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has created an unprecedented and daunting challenge for humanity to survive. This has also affected the sporting events across the globe as the majority of the tournaments have been cancelled or postponed as a result. For life to return to pre-pandemic normalcy, an effective and safe vaccination program needs to be implemented, be readily accessible, widely available, and affordable at the same time.
Objectives. In this review, we analyze various challenges which demonstrate that COVID-19 is far from over.
Methods. A systematic literature search was conducted on PubMed, ScienceDirect, Medline, Google Scholar, and Scopus from the commencement of the COVID-19 pandemic to 22 June 2021. The current report is a summary of data regarding challenges faced by the COVID-19 vaccination campaign and the challenges for a transition toward normalcy, especially for big sports events.
Results. The current COVID-19 pandemic has likely resulted in sporting events and tournaments being canceled, postponed, or held without or with restricted spectators around the world. A combination of measures including prompt vaccination with the beneficial impact of the vaccines in reducing the severity of disease, advances in treatment, expanded use of diagnostics and better implementation of public-health policies are a necessity. Following this implementation, a transition toward normality could be expected when the mortality rate of COVID-19 simulates the average influenza statistics, with public-health measures continuing to play an important role worldwide.
Conclusion. The authors believe that COVID-19 will be endemic in the human population, similar to seasonal influenza and that COVID-19 vaccines will be included as an add-on to seasonal influenza vaccinations, being administered every winter for at least the next few decades. With adequate vaccination, the sporting world will be able to withstand the challenges and resume global events, returning to pre-Covid levels of normalcy.
Full-Text [PDF 480 kb]   (303 Downloads)    
 
 
APPLICABLE REMARKS
  • • To significantly reduce deaths from COVID-19, a combination of measures including prompt vaccination (especially for the at-risk population) with the beneficial impact of the vaccines in reducing the severity of disease, advances in treatment, expanded use of diagnostics, and better implementation of public-health policies are a necessity.
  • • Following this implementation, a transition toward normality could be expected when the mortality rate of COVID-19 simulates the average influenza statistics, with public-health measures continuing to play an important role worldwide. There has to be a realistic view concerning the duration of immunity and long-term vaccine safety (given the limited data available so far). Herd immunity might take longer than expected to establish.
  • • The authors feel that COVID-19 will be endemic in the human population like seasonal influenza and COVID-19 vaccines would be incorporated in seasonal influenza vaccinations as an add-on, being administered every winter for the next few decades at least! With adequate vaccination, the sporting world can withstand the challenges and hope to restart the global events that are getting back to normalcy as pre-COVID times.

Type of Study: Review Article | Subject: Exercise, Training and Health
Received: 2021/06/22 | Accepted: 2021/07/2 | Published: 2021/08/20 | ePublished: 2021/08/20

References
1. Liu Y, Yang Y, Zhang C, Huang F, Wang F, Yuan J, et al. Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury. Science China Life sciences. 2020;63(3):364-74. [DOI:10.1007/s11427-020-1643-8] [PMID] [PMCID]
2. Wu A, Peng Y, Huang B, Ding X, Wang X, Niu P, et al. Genome Composition and Divergence of the Novel Coronavirus (2019-nCoV) Originating in China. Cell host & microbe. 2020;27(3):325-8. https://doi.org/10.1016/j.chom.2021.02.016 [DOI:10.1016/j.chom.2020.02.001] [PMID]
3. Graham RL, Baric RS. Recombination, reservoirs, and the modular spike: mechanisms of coronavirus cross-species transmission. Journal of virology. 2010;84(7):3134-46. [DOI:10.1128/JVI.01394-09] [PMID] [PMCID]
4. Worldometer. COVID-19 coronavirus pandemic. 2021 [Available from: https://www.worldometers.info/coronavirus/.
5. Musa S, Dergaa I, Mansy O. The puzzle of Autism in the time of COVID 19 pandemic:"Light it up Blue". Psychology and Education Journal. 2021;58(5):1861-73.
6. Varma A, Dergaa I, Mohammed AR, Abubaker M, Al Naama A, Mohammed S, et al. Covid-19 and diabetes in primary care - How do hematological parameters present in this cohort? Expert review of endocrinology & metabolism. 2021;16(3):147-53. [DOI:10.1080/17446651.2021.1909472] [PMID]
7. Trabelsi K, Ammar A, Masmoudi L, Boukhris O, Chtourou H, Bouaziz B, et al. Globally altered sleep patterns and physical activity levels by confinement in 5056 individuals: ECLB COVID-19 international online survey. Biology of Sport. 2021;38(4):495-506.
8. Trabelsi K, Ammar A, Masmoudi L, Boukhris O, Chtourou H, Bouaziz B, et al. Sleep Quality and Physical Activity as Predictors of Mental Wellbeing Variance in Older Adults during COVID-19 Lockdown: ECLB COVID-19 International Online Survey. International journal of environmental research and public health. 2021;18(8).
9. Sharma O, Sultan AA, Ding H, Triggle CR. A Review of the Progress and Challenges of Developing a Vaccine for COVID-19. Frontiers in immunology. 2020;11:585354. [DOI:10.3389/fimmu.2020.585354] [PMID] [PMCID]
10. Varma A, Dergaa I, Ashkanani M, Musa S, Zidan M. Analysis of Qatar's successful public health policy in dealing with the Covid-19 pandemic. International Journal of Medical Reviews and Case Reports. 2021;5(2):6-11.. [DOI:10.5455/IJMRCR.covid-19-qatar]
11. Varma A, Dergaa I, Zidan M, Chaabane M. Covid-19:"Drive thru swabbing hubs"-safe and effective testing for travellers. The Journal of Medical Research. 2020;6(6):311-2. [DOI:10.31254/jmr.2020.6613]
12. Varma A, Abubaker M, Dergaa I. Extensive Saliva based COVID-19 testing-the way forward to curtail the global pandemic. The Journal of Medical Research. 2020;6(6):309-10. [DOI:10.31254/jmr.2020.6612]
13. Musa S, Al Baker W, Al Muraikhi H, Nazareno D, Al Naama A, Dergaa I. Wellness Program Within Primary Health Care: How to Avoid "No Show" to Planned Appointments?-A Patient-Centred Care Perspective. Physical Activity and Health. 2021;5(1). [DOI:10.5334/paah.90]
14. Safiabadi Tali SH, LeBlanc JJ, Sadiq Z, Oyewunmi OD, Camargo C, Nikpour B, et al. Tools and Techniques for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)/COVID-19 Detection. Clinical microbiology reviews. 2021;34(3). [DOI:10.1128/CMR.00228-20] [PMID] [PMCID]
15. Fiore JR, Centra M, De Carlo A, Granato T, Rosa A, Sarno M, et al. Results from a survey in healthy blood donors in South Eastern Italy indicate that we are far away from herd immunity to SARS-CoV-2. Journal of Medical Virology. 2021;93(3):1739-42. [DOI:10.1002/jmv.26425] [PMID] [PMCID]
16. World Health Organization. Coronavirus disease (COVID-19): Herd immunity, lockdowns and COVID-19 2020 [Available from: https://www.who.int/news-room/q-a-detail/herd-immunity-lockdowns-and-covid-19.
17. Randolph HE, Barreiro LB. Herd Immunity: Understanding COVID-19. Immunity. 2020;52(5):737-41. [DOI:10.1016/j.immuni.2020.04.012] [PMID] [PMCID]
18. Our World in Data. Coronavirus (COVID-19) Vaccinations [Available from: https://ourworldindata.org/covid-vaccinations
19. Tanne JH. Covid-19: FDA panel votes to authorise Pfizer BioNTech vaccine. BMJ. 2020;371:m4799. [DOI:10.1136/bmj.m4799] [PMID]
20. Mishra SK, Tripathi T. One year update on the COVID-19 pandemic: Where are we now? Acta tropica. 2021;214:105778. [DOI:10.1016/j.actatropica.2020.105778] [PMID] [PMCID]
21. Chung YH, Beiss V, Fiering SN, Steinmetz NF. COVID-19 Vaccine Frontrunners and Their Nanotechnology Design. ACS Nano. 2020;14(10):12522-37. [DOI:10.1021/acsnano.0c07197] [PMID] [PMCID]
22. Food and Drug Administration. Coronavirus (COVID-19) Update: FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine for Emergency Use in Adolescents in Another Important Action in Fight Against Pandemic. 2021 [Available from: https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-pfizer-biontech-covid-19-vaccine-emergency-use.
23. Kronbichler A, Kresse D, Yoon S, Lee KH, Effenberger M, Shin JI. Asymptomatic patients as a source of COVID-19 infections: A systematic review and meta-analysis. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases. 2020;98:180-6. [DOI:10.1016/j.ijid.2020.06.052] [PMID] [PMCID]
24. Deeks J, Dinnes J, Takwoingi Y, Davenport C, Spijker R, Taylor-Phillips S, et al. Antibody tests for identification of current and past infection with SARS‐CoV‐2. Cochrane Database of Systematic Reviews. 2020;6(6). [DOI:10.1002/14651858.CD013652] [PMID] [PMCID]
25. Seow J, Graham C, Merrick B, Acors S, Pickering S, Steel KJA, et al. Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans. Nature Microbiology. 2020;5(12):1598-607. [DOI:10.1038/s41564-020-00813-8] [PMID] [PMCID]
26. Ward H, Cooke G, Atchison C, Whitaker M, Elliott J, Moshe M, et al. Declining prevalence of antibody positivity to SARS-CoV-2: a community study of 365,000 adults. medRxiv. 2020:2020.10.26.20219725. [DOI:10.1101/2020.10.26.20219725]
27. Sun Y, Ho M. Emerging antibody-based therapeutics against SARS-CoV-2 during the global pandemic. Antibody Therapeutics. 2020;3(4):246-56. [DOI:10.1093/abt/tbaa025] [PMID] [PMCID]
28. Dawood AA. Mutated COVID-19 may foretell a great risk for mankind in the future. New Microbes and New Infections. 2020;35:100673. [DOI:10.1016/j.nmni.2020.100673] [PMID] [PMCID]
29. Sevajol M, Subissi L, Decroly E, Canard B, Imbert I. Insights into RNA synthesis, capping, and proofreading mechanisms of SARS-coronavirus. Virus research. 2014;194:90-9. [DOI:10.1016/j.virusres.2014.10.008] [PMID] [PMCID]
30. Smith EC, Blanc H, Surdel MC, Vignuzzi M, Denison MR. Coronaviruses lacking exoribonuclease activity are susceptible to lethal mutagenesis: evidence for proofreading and potential therapeutics. PLoS pathogens. 2013;9(8):e1003565. [DOI:10.1371/journal.ppat.1003565] [PMID] [PMCID]
31. Fauver JR, Petrone ME, Hodcroft EB, Shioda K, Ehrlich HY, Watts AG, et al. Coast-to-Coast Spread of SARS-CoV-2 during the Early Epidemic in the United States. Cell. 2020;181(5):990-6.e5. [DOI:10.1016/j.cell.2020.04.021] [PMID] [PMCID]
32. Wu A, Peng Y, Huang B, Ding X, Wang X, Niu P, et al. Genome Composition and Divergence of the Novel Coronavirus (2019-nCoV) Originating in China. Cell host & microbe. 2020;27(3):325-8. https://doi.org/10.1016/j.chom.2021.02.016 [DOI:10.1016/j.chom.2020.02.001] [PMID]
33. Boni MF, Gog JR, Andreasen V, Feldman MW. Epidemic dynamics and antigenic evolution in a single season of influenza A. Proceedings of the Royal Society B: Biological Sciences. 2006;273(1592):1307-16. [DOI:10.1098/rspb.2006.3466] [PMID] [PMCID]
34. Sehra ST, Salciccioli JD, Wiebe DJ, Fundin S, Baker JF. Maximum Daily Temperature, Precipitation, Ultraviolet Light, and Rates of Transmission of Severe Acute Respiratory Syndrome Coronavirus 2 in the United States. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. 2020;71(9):2482-7. [DOI:10.1093/cid/ciaa681] [PMID] [PMCID]
35. Ren L, Zhang Y, Li J, Xiao Y, Zhang J, Wang Y, et al. Genetic drift of human coronavirus OC43 spike gene during adaptive evolution. Scientific Reports. 2015;5(1):11451. [DOI:10.1038/srep11451] [PMID] [PMCID]
36. Vijgen L, Keyaerts E, Lemey P, Moës E, Li S, Vandamme AM, et al. Circulation of genetically distinct contemporary human coronavirus OC43 strains. Virology. 2005;337(1):85-92. [DOI:10.1016/j.virol.2005.04.010] [PMID] [PMCID]
37. Chibo D, Birch C. Analysis of human coronavirus 229E spike and nucleoprotein genes demonstrates genetic drift between chronologically distinct strains. The Journal of general virology. 2006;87(Pt 5):1203-8. [DOI:10.1099/vir.0.81662-0] [PMID]
38. Guan Y, Zheng BJ, He YQ, Liu XL, Zhuang ZX, Cheung CL, et al. Isolation and characterization of viruses related to the SARS coronavirus from animals in southern China. Science (New York, NY). 2003;302(5643):276-8. [DOI:10.1126/science.1087139] [PMID]
39. Song HD, Tu CC, Zhang GW, Wang SY, Zheng K, Lei LC, et al. Cross-host evolution of severe acute respiratory syndrome coronavirus in palm civet and human. Proceedings of the National Academy of Sciences of the United States of America. 2005;102(7):2430-5. [DOI:10.1073/pnas.0409608102] [PMID] [PMCID]
40. Sui J, Aird DR, Tamin A, Murakami A, Yan M, Yammanuru A, et al. Broadening of Neutralization Activity to Directly Block a Dominant Antibody-Driven SARS-Coronavirus Evolution Pathway. PLoS pathogens. 2008;4(11):e1000197. [DOI:10.1371/journal.ppat.1000197] [PMID] [PMCID]
41. BBC News. 'New variant' of coronavirus identified in England 2020 [Available from: https://www.bbc.com/news/health-55308211.
42. Pharmaceutical Technology. Coronavirus: A timeline of how the deadly COVID-19 outbreak is evolving 2021 [Available from: https://www.pharmaceutical-technology.com/news/coronavirus-a-timeline-of-how-the-deadly-outbreak-evolved/.
43. Yang R, Kraft Colleen S. Plague: Recognition, Treatment, and Prevention. Journal of Clinical Microbiology.56(1):e01519-17. [DOI:10.1128/JCM.01519-17]
44. Butcher GA, Mitchell GH. The role of Plasmodium knowlesi in the history of malaria research. Parasitology. 2018;145(1):6-17. [DOI:10.1017/S0031182016001888] [PMID]
45. Hennessey K, Schluter WW, Wang X, Boualam L, Jee Y, Mendoza-Aldana J, et al. Are we there yet? Assessing achievement of vaccine-preventable disease goals in WHO's Western Pacific Region. Vaccine. 2014;32(34):4259-66. [DOI:10.1016/j.vaccine.2014.02.093] [PMID]
46. Meyer H, Ehmann R, Smith GL. Smallpox in the Post-Eradication Era. Viruses. 2020;12(2). [DOI:10.3390/v12020138] [PMID] [PMCID]
47. Sparrow AK, Brosseau LM, Harrison RJ, Osterholm MT. Protecting Olympic Participants from Covid-19 - The Urgent Need for a Risk-Management Approach. New England Journal of Medicine. 2021;385(1):e2. [DOI:10.1056/NEJMp2108567] [PMID]
48. Dergaa I, Varma A, Tabben M, Ali Malik R, Sheik S, Vedasalam S, et al. Organising football matches with spectators during the COVID-19 pandemic: What can we learn from the Amir Cup Football Final of Qatar 2020? A call for action. Biology of Sport. 2021;38(4):677-81. [DOI:10.5114/biolsport.2021.103568]
49. McLarnon M, Heron N. The COVID-19 athlete passport: a tool for managing athlete COVID-19 status surrounding the Tokyo 2020 Olympic games. The Physician and Sportsmedicine. 2021:1-4. [DOI:10.1080/00913847.2021.1885964] [PMID]

Add your comments about this article : Your username or Email:
CAPTCHA

Send email to the article author


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2021 CC BY-NC 4.0 | Annals of Applied Sport Science

Designed & Developed by : Yektaweb